Back to Search Start Over

Definitive chemoradiotherapy for a patient with anal cancer after renal transplantation.

Authors :
Kashiwagi T
Sakanaka K
Inoo H
Hirashima H
Fujii K
Mizowaki T
Source :
International cancer conference journal [Int Cancer Conf J] 2024 Mar 20; Vol. 13 (3), pp. 223-229. Date of Electronic Publication: 2024 Mar 20 (Print Publication: 2024).
Publication Year :
2024

Abstract

Patients after renal transplantation are susceptible to secondary malignancies, including anal squamous cell carcinoma. Chemoradiotherapy is the standard treatment for anal squamous cell carcinoma; however, typical irradiation fields for anal cancer encompass a transplanted kidney located in the right iliac fossa, which causes complete renal dysfunction. Thus, typical irradiation fields are not feasible for this population. Additionally, standard concurrent chemotherapy demonstrates nephrotoxicity. Here, we report a case of modified definitive chemoradiotherapy for a 40-year-old patient with locally advanced perianal squamous cell carcinoma after renal transplantation whose abdominoperineal resection was difficult because of a history of repeated open surgeries and long-term steroids. We modified the cranial side of the elective nodal irradiation fields in this case to spare the transplanted kidney, considering the lymph chains of the perianal tumor. We then used continuous 5-fluorouracil to avoid nephrotoxicity of mitomycin C, considering his life expectancy. Modified definitive chemoradiotherapy achieved complete remission with expected toxicities. Now, approximately five years after the procedure, the patient remains disease-free, preserving anal and renal function. Definitive chemoradiotherapy using modified irradiation fields and chemotherapy may be an option for patients with anal squamous cell carcinoma after renal transplantation.<br />Competing Interests: Conflict of interestThe authors declare no conflicts of interest.<br /> (© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)

Details

Language :
English
ISSN :
2192-3183
Volume :
13
Issue :
3
Database :
MEDLINE
Journal :
International cancer conference journal
Publication Type :
Academic Journal
Accession number :
38962035
Full Text :
https://doi.org/10.1007/s13691-024-00666-6